Search results for " Molecular Medicine"

showing 10 items of 39 documents

2,3-Dihydrobenzofuran privileged structures as new bioinspired lead compounds for the design of mPGES-1 inhibitors

2016

International audience; 2,3-Dihydrobenzofurans are proposed as privileged structures and used as chemical platform to design small compound libraries. By combining molecular docking calculations and experimental verification of biochemical interference, we selected some potential inhibitors of microsomal prostaglandin E2 synthase (mPGES)-1. Starting from low affinity natural product 1, by our combined approach we identified the compounds 19 and 20 with biological activity in the low micromolar range. Our data suggest that the 2,3-dihydrobenzofuran derivatives might be suitable bioinspired lead compounds for development of new generation mPGES-1 inhibitors with increased affinity.

0301 basic medicine300323-Dihydrobenzofuran privileged structure; Cancer; Inflammation; Molecular docking; mPGES-1 inhibitors; Biochemistry; Clinical Biochemistry; Molecular Biology; Molecular Medicine; Organic Chemistry; Drug Discovery3003 Pharmaceutical Science; 3003Amino Acid MotifsClinical BiochemistryGene ExpressionPharmaceutical Science01 natural sciencesClinical biochemistryBiochemistry[ CHIM ] Chemical SciencesProtein Structure Secondary[ SDV.CAN ] Life Sciences [q-bio]/Cancerchemistry.chemical_compoundLow affinityDrug DiscoveryEnzyme Inhibitors23-Dihydrobenzofuran privileged structure; Molecular docking; mPGES-1 inhibitors; Cancer; InflammationProstaglandin-E SynthasesCancerAnti-Inflammatory Agents Non-SteroidalBiological activityProto-Oncogene Proteins c-metIntramolecular OxidoreductasesMolecular Docking SimulationMolecular dockingMolecular Medicinelipids (amino acids peptides and proteins)Cell SurvivalStereochemistryMolecular Sequence Data2Antineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/Cancer3-Dihydrobenzofuran privileged structureInhibitory Concentration 50Structure-Activity Relationship03 medical and health sciencesCell Line TumorMicrosomesHumans[CHIM]Chemical SciencesMolecular BiologyBenzofuransInflammationNatural product010405 organic chemistryDrug Discovery3003 Pharmaceutical ScienceOrganic ChemistryEpithelial CellsmPGES-1 inhibitorsCombinatorial chemistryCombined approach0104 chemical sciences030104 developmental biologychemistryDrug DesignDrug Screening Assays Antitumor
researchProduct

Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody

2016

The kinase receptor encoded by the Met oncogene is a sensible target for cancer therapy. The chimeric monovalent Fab fragment of the DN30 monoclonal antibody (MvDN30) has an odd mechanism of action, based on cell surface removal of Met via activation of specific plasma membrane proteases. However, the short half-life of the Fab, due to its low molecular weight, is a severe limitation for the deployment in therapy. This issue was addressed by increasing the Fab molecular weight above the glomerular filtration threshold through the duplication of the constant domains, in tandem (DCD-1) or reciprocally swapped (DCD-2). The two newly engineered molecules showed biochemical properties comparable…

0301 basic medicineCancer ResearchMice SCIDCancer targeted therapy0302 clinical medicineMice Inbred NODEpidermal growth factor receptorPhosphorylationbiologyChemistryImmunoglobulin Fab FragmentsAntibodies MonoclonalGeneral MedicineArticlesProto-Oncogene Proteins c-metHalf-lifeCell biologyOncology030220 oncology & carcinogenesisColonic NeoplasmsMetMolecular MedicineFemalemedicine.symptomSignal transductionAntibodySignal Transductionmedicine.drug_classColonAntibody; Cancer targeted therapy; Fab; Half-life; Met; Protein engineering; Cancer Research; Genetics; Molecular MedicineAntineoplastic AgentsMonoclonal antibody03 medical and health sciencesImmunoglobulin Fab FragmentsProtein DomainsCell Line TumormedicineGeneticsAnimalsHumansFabAntibodyCell growthMolecular biology030104 developmental biologyHEK293 CellsMechanism of actionHepatocyte Growth Factor ReceptorA549 Cellsbiology.proteinProtein engineering
researchProduct

Gene therapy for chondral and osteochondral regeneration: is the future now?

2017

Gene therapy might represent a promising strategy for chondral and osteochondral defects repair by balancing the management of temporary joint mechanical incompetence with altered metabolic and inflammatory homeostasis. This review analysed preclinical and clinical studies on gene therapy for the repair of articular cartilage defects performed over the last 10 years, focussing on expression vectors (non-viral and viral), type of genes delivered and gene therapy procedures (direct or indirect). Plasmids (non-viral expression vectors) and adenovirus (viral vectors) were the most employed vectors in preclinical studies. Genes delivered encoded mainly for growth factors, followed by transcripti…

0301 basic medicineCartilage ArticularExpression vectorPathologymedicine.medical_specialtyCell signalingCartilage repair; Expression vectors; Gene therapy procedures; Osteoarthritis; Regenerative medicine; Molecular Medicine; Molecular Biology; Pharmacology; Cellular and Molecular Neuroscience; Cell BiologyBone RegenerationInflammatory arthritisGenetic enhancementGene therapy procedureOsteoarthritisViral vector03 medical and health sciencesCellular and Molecular NeuroscienceCartilage repairChondrocytesInterferonSettore BIO/13 - Biologia ApplicataOsteoarthritismedicineAnimalsHumansRegenerationMolecular BiologyPharmacologyExpression vectorbusiness.industryRegeneration (biology)Cell BiologyGenetic Therapymedicine.disease030104 developmental biologyRegenerative medicineCancer researchMolecular MedicineOsteoarthritibusinessmedicine.drugCellular and molecular life sciences : CMLS
researchProduct

New insights into the mechanism of action of pyrazolo[1,2-a]benzo[1,2,3,4]tetrazin-3-one derivatives endowed with anticancer potential

2018

Due to the scarce biological profile, the pyrazolo[1,2-a]benzo[1,2,3,4]tetrazine-3-one scaffold (PBT) has been recently explored as promising core for potential anticancer candidates. Several suitably decorated derivatives (PBTs) exhibited antiproliferative activity in the low-micromolar range associated with apoptosis induction and cell cycle arrest on S phase. Herein, we selected the most active derivatives and submitted them to further biological explorations to deepen the mechanism of action. At first, a DNA targeting is approached by means of flow Linear Dichroism experiments so as to evaluate how small planar molecules might interact with DNA, including the interference with the catal…

0301 basic medicineCell cycle checkpointPyrazolo[1TetrazolesBiochemistrychemistry.chemical_compound0302 clinical medicineSalmonAntiproliferative; DNA-interacting; Intercalation; Linear dichroism; Molecular docking; Pyrazolo[12-a]benzo[1234]tetrazin-3-one; Topoisomerase II; Biochemistry; Molecular MedicineDrug DiscoveryDNA-interactingBase PairingADMEbiologyIntercalating AgentsMolecular Docking Simulation030220 oncology & carcinogenesisMolecular Medicinemedicine.symptomtopoisomerase II3StereochemistryIn silico2Antineoplastic Agentslinear dichroism03 medical and health sciencesantiproliferativeintercalationmedicineAnimalsHumansDNA Cleavage2-a]benzo[1Pharmacology4]tetrazin-3-oneBinding SitesTopoisomeraseOrganic ChemistryDNAmolecular dockingSettore CHIM/08 - Chimica FarmaceuticaChemical spaceProtein Structure TertiaryDNA Topoisomerases Type II030104 developmental biologyMechanism of actionchemistryCatalytic cyclebiology.proteinpyrazolo[12-a]benzo[1234]tetrazin-3-oneDNAChemical Biology & Drug Design
researchProduct

Genetics and Gene Therapy of Anderson-Fabry Disease.

2018

Fabry's disease is a genetic disorder of X-linked inheritance caused by mutations in the alpha galactosidase A gene resulting in deficiency of this lysosomal enzyme. The progressive accumulation of glycosphingolipids, caused by the inadequate enzymatic activity, is responsible of organ dysfunction and thus of clinical manifestations. In the presence of a high clinical suspicion, a careful physical examination and specific laboratory tests are required, finally diagnosis of Fabry's disease is confirmed by the demonstration of absence or reduced alpha-galactosidase A enzyme activity in hemizygous men and gene typing in heterozygous females; in fact the performance of enzymatic activity assay …

0301 basic medicineGenetic enhancementChaperone therapyDisease030204 cardiovascular system & hematologyBioinformaticsMice0302 clinical medicineAlpha galactosidase ADrug DiscoveryGenetics (clinical)KidneybiologyTrihexosylceramidesGenetic disorderEnzyme replacement therapyDependovirusRecombinant ProteinsAlpha galactosidase A; Chaperone therapy; Enzyme replacement therapy; Fabry disease; Gene therapy; Viral vectors; Molecular Medicine; Molecular Biology; Genetics; Drug Discovery3003 Pharmaceutical Science; Genetics (clinical)Isoenzymesmedicine.anatomical_structureMolecular Medicinemedicine.symptomGenetic Vectors03 medical and health sciencesGene therapyViral vectorRare DiseasesGeneticGeneticsmedicineAnimalsHumansEnzyme Replacement TherapyMolecular BiologyAlpha-galactosidasebusiness.industryDrug Discovery3003 Pharmaceutical ScienceOrgan dysfunctionGenetic Therapymedicine.diseaseFabry diseaseDisease Models Animal030104 developmental biologyalpha-GalactosidaseMutationbiology.proteinFabry DiseasebusinessBiomarkersCurrent gene therapy
researchProduct

Diabetic microangiopathy: Pathogenetic insights and novel therapeutic approaches.

2017

Diabetic microangiopathy, including retinopathy, is characterized by abnormal growth and leakage of small blood vessels, resulting in local edema and functional impairment of the depending tissues. Mechanisms leading to the impairment of microcirculation in diabetes are multiple and still largely unclear. However, a dysregulated vascular regeneration appears to play a key role. In addition, oxidative and hyperosmolar stress, as well as the activation of inflammatory pathways triggered by advanced glycation end-products and toll-like receptors, have been recognized as key underlying events. Here, we review recent knowledge on cellular and molecular pathways of microvascular disease in diabet…

0301 basic medicineGlycation End Products AdvancedPhysiologyDiabetes retinopathyGlycation End ProductsDiseaseFibroblast growth factorHMGB1DiabeteMicrocirculationCapillary Permeability03 medical and health sciencesGlycationDiabetes mellitusmedicineSettore MED/05 - Patologia ClinicaAnimalsHumansCellular and molecular pathways; Diabetes; Diabetes retinopathy; Microangiopathy; Physiology; Molecular Medicine; PharmacologyNeovascularizationPharmacologyPathologicbiologyNeovascularization Pathologicbusiness.industryMicrocirculationMicroangiopathyDiabetesToll-Like Receptorsmedicine.diseasePrognosisCellular and molecular pathways; Diabetes; Diabetes retinopathy; Microangiopathy; Animals; Capillary Permeability; Diabetic Angiopathies; Glycation End Products Advanced; Humans; Inflammation Mediators; Microcirculation; Microvessels; Neovascularization Pathologic; Oxidative Stress; Prognosis; Signal Transduction; Toll-Like ReceptorsOxidative Stress030104 developmental biologyCellular and molecular pathwaysMicroangiopathyImmunologyMicrovesselsbiology.proteinMolecular MedicineAdvancedCellular and molecular pathwayInflammation MediatorsbusinessDiabetic AngiopathiesRetinopathySignal TransductionVascular pharmacology
researchProduct

Combined platelet-rich plasma and lipofilling treatment provides great improvement in facial skin-induced lesion regeneration for scleroderma patient…

2017

Background The use of stem cells, including mesenchymal stem cells (MSCs), for regenerative medicine is gaining interest for the clinical benefits so far obtained in patients. This study investigates the use of adipose autologous tissue in combination with platelet-rich plasma (PRP) to improve the clinical outcome of patients affected by systemic sclerosis (SSc). Methods Adipose-derived mesenchymal stem cells (AD-MSCs) and PRPs were purified from healthy donors and SSc patients. The multilineage differentiation potential of AD-MSCs and their genotypic–phenotypic features were investigated. A cytokine production profile was evaluated on AD-MSCs and PRPs from both healthy subjects and SSc pat…

0301 basic medicineMalePathologyCell- and Tissue-Based TherapyAdipose tissueMedicine (miscellaneous)Gene ExpressionRegenerative MedicineCell therapyCell therapySystemic sclerosiAdipose-derived mesenchymal stem cells; Cell therapy; Lipofilling; Mesenchymal stem cells; Platelet-rich plasma; Regenerative medicine; Systemic sclerosis; Medicine (miscellaneous); Molecular Medicine; Biochemistry Genetics and Molecular Biology (miscellaneous); Cell Biologylcsh:QD415-436skin and connective tissue diseasesMesenchymal stem cellSkinAged 80 and overlcsh:R5-920integumentary systemCell DifferentiationStromal vascular fractionMiddle Agedmedicine.anatomical_structureAdipose TissueMolecular MedicineCytokinesSystemic sclerosisFemaleStem celllcsh:Medicine (General)Adultmedicine.medical_specialtyPrimary Cell CultureConnective tissueNeovascularization PhysiologicMesenchymal Stem Cell TransplantationBiochemistry Genetics and Molecular Biology (miscellaneous)lcsh:Biochemistry03 medical and health sciencesPlatelet-rich plasmaAntigens CDAdipose-derived mesenchymal stem cellsmedicineHumansCell ProliferationAdipose-derived mesenchymal stem cellLipofillingScleroderma Systemicbusiness.industryRegeneration (biology)ResearchMesenchymal stem cellMesenchymal Stem CellsCell Biology030104 developmental biologyPlatelet-rich plasmaImmunologybusinessStem cell researchtherapy
researchProduct

Parkinson's disease: towards better preclinical models and personalized treatments.

2016

Non peer reviewed

0301 basic medicineParkinson's diseaseeducationMEDLINEBioinformatics03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineDEFICITSMedicineAnimalsHumansMolecular BiologyPharmacologybusiness.industryParkinson DiseaseCell Biologymedicine.diseaseMolecular medicine3. Good healthMICE030104 developmental biologyNeuroprotective AgentsCell Biology; Molecular Biology; Molecular Medicine; Pharmacology; Cellular and Molecular NeuroscienceMolecular Medicine3111 Biomedicinebusiness030217 neurology & neurosurgeryCellular and molecular life sciences : CMLS
researchProduct

Chemoresistance and chemosensitization in cholangiocarcinoma

2017

One of the main difficulties in the management of patients with advanced cholangiocarcinoma (CCA) is their poor response to available chemotherapy. This is the result of powerful mechanisms of chemoresistance (MOC) of quite diverse nature that usually act synergistically. The problem is often worsened by altered MOC gene expression in response to pharmacological treatment. Since CCA includes a heterogeneous group of cancers their genetic signature coding for MOC genes is also diverse; however, several shared traits have been defined. Some of these characteristics are shared with other types of liver cancer, namely hepatocellular carcinoma and hepatoblastoma. An important goal in modern onco…

0301 basic medicinePharmacologybile ductschemotherapydrug delivery systems0302 clinical medicineChemosensitizationantineoplastic agentsmolecular biologyReceptorhumansreceptor protein-tyrosine kinasesmedia_commonapoptosisgene expression regulationbile duct neoplasmsDrug Resistance Multipletargeted therapiesGene Expression Regulation Neoplasticmultiplebiliary cancer; chemotherapy; liver cancer; multidrug resistance; targeted therapies; antineoplastic agents; apoptosis; bile duct neoplasms; bile ducts; cell survival; cholangiocarcinoma; drug delivery systems; drug resistance multiple; drug resistance; neoplasm; epithelial cells; gene expression regulation neoplastic; genetic therapy; humans; protein kinase inhibitors; receptor protein-tyrosine kinases; signal transduction; treatment outcome; molecular medicine; molecular biology030220 oncology & carcinogenesisHepatocellular carcinomabiliary cancerLiver cancercholangiocarcinomaTyrosine kinasesignal transductionDrugHepatoblastomamedia_common.quotation_subjectcell survivalPharmacological treatmentliver cancer03 medical and health sciencesmultidrug resistancemedicinemolecular medicinedrug resistancebusiness.industrymedicine.diseaseepithelial cellsneoplasticprotein kinase inhibitors030104 developmental biologyDrug Resistance NeoplasmCancer researchtreatment outcomebusinessneoplasmgenetic therapy
researchProduct

A Library-Based Screening Strategy for the Identification of DARPins as Ligands for Receptor-Targeted AAV and Lentiviral Vectors

2021

Delivering genes selectively to the therapeutically relevant cell type is among the prime goals of vector development. Here, we present a high-throughput selection and screening process that identifies designed ankyrin repeat proteins (DARPins) optimally suited for receptor-targeted gene delivery using adeno-associated viral (AAV) and lentiviral (LV) vectors. In particular, the process includes expression, purification, and in situ biotinylation of the extracellular domains of target receptors as Fc fusion proteins in mammalian cells and the selection of high-affinity binders by ribosome display from DARPin libraries each covering more than 1012 variants. This way, DARPins specific for the …

0301 basic medicinelcsh:QH426-470610 Medicine & healthComputational biologyQH426-470BiologyGene deliveryArticleViral vector03 medical and health sciences0302 clinical medicine1311 GeneticsLV10019 Department of Biochemistry1312 Molecular BiologyGeneticsVector (molecular biology)lcsh:QH573-671Molecular Biology030304 developmental biology0303 health sciencesQH573-671lcsh:Cytology10179 Institute of Medical Microbiologyribosome displayCorrectionAAVFusion proteinlcsh:GeneticsCD105NKp46DARPin030104 developmental biologyGluA4DARPin1313 Molecular Medicine030220 oncology & carcinogenesisBiotinylationRibosome displayreceptor-targeted viral vectors570 Life sciences; biologyMolecular MedicineAnkyrin repeatCytologyMolecular Therapy - Methods & Clinical Development
researchProduct